Aquestive Therapeutics Reports Q2 2026 Financial Results With $5.2 Million Revenue

Aquestive Therapeutics reported a revenue of $5.2 million for the second quarter of 2026, reflecting a significant increase compared to the previous year. The company also provided a business update, highlighting ongoing developments in its product pipeline and strategic initiatives.

During the earnings call, management discussed their focus on advancing key programs and the potential impact on future growth. The company remains optimistic about its trajectory as it continues to navigate the evolving healthcare landscape.